Efficacy and safety of CD30-targeted chimeric antigen receptor T-cell therapy for lymphoma: a meta-analysis.
CD30-targeted CAR-T cell therapy shows consistent benefit across lymphoma studies, offering pooled evidence to guide treatment decisions for patients with limited options.
This meta-analysis systematically evaluates the efficacy and safety of CD30-targeted CAR-T cell therapy across published studies in lymphoma patients. The findings provide a pooled evidence base for CD30-CAR-T as a treatment strategy for this hematologic malignancy.
What the study was
- Study design
- Meta-analysis
- Population
- Patients with CD30+ lymphoma treated with CAR-T cell therapy
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- BMC Cancer
Why it surfaced
Meta-analysis synthesizing CAR-T evidence for lymphoma — directly on-watchlist, high design quality, strong clinical relevance for a hematologic malignancy with ongoing unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.